Table 1 Baseline clinical characteristics of patients receiving high dose chemoradiotherapy
Variable | N = 57 |
|---|---|
Age at diagnosis, n (%) | Â |
 Median, y (range) | 59 (29–84) |
  < 60y | 30 (52.6) |
  ≥ 60y | 27 (47.4) |
Sex, n (%) | Â |
 Male | 44 (77.2) |
 Female | 13 (22.8) |
Baseline CEA (mg/mL) | Â |
 < 5.00 mg/mL | 35 (61.4) |
 ≥ 5.00 mg/mL | 22 (38.6) |
T stage, n (%) | Â |
 T1 | 1 (1.8) |
 T2 | 10 (17.5) |
 T3 | 33 (57.9) |
 T4 | 13 (22.8) |
N stage, n (%) | Â |
 N0 | 21 (36.8) |
 N1 | 23 (40.4) |
 N2 | 13 (22.8) |
AJCC/UICC stage, n (%) | Â |
 Stage I | 5 (8.8) |
 Stage II | 16 (28.1) |
 Stage III | 36 (63.2) |
Histopathology (differentiation), n (%) |  |
 Poorly differentiated | 8 (14.0) |
 Moderately differentiated | 33 (57.9) |
 Undefined | 16 (28.1) |
Distance to the anal verge, n (%) |  |
 Median, cm (range) | 3.0 (0.0–10.0) |
  ≤ 5.0 cm | 53 (93.0) |
  > 5.0 cm | 4 (7.0) |
Length, n (%) | Â |
 Median, cm (range) | 5.0 (2.0–11.0) |
  < 5.0 cm | 28 (49.1) |
  ≥ 5.0 cm | 29 (50.9) |
Adjacent organ invasion, n (%) | Â |
 Yes | 9 (15.8) |
 No | 48 (84.2) |
Comorbidities, n (%) | Â |
 Yes | 10 (17.5) |
 No | 47 (82.5) |